Postmenopausal osteoporosis — an interdisciplinary problem of modern

Postmenopausal osteoporosis is an important interdisciplinary problem of modern medicine. The presented lecture highlights modern approaches to the diagnosis, prognosis and treatment of this pathology. The leading role in the detection of osteoporotic changes is played by radiation diagnostic methods that determine the level of bone mineral density - the equivalent of bone mass. In order to study metabolic disorders of bone tissue, laboratory methods are used that evaluate the activity of bone synthesis and resorption. When predicting osteoporotic fractures, the FRAX model is widely used, which determines the likelihood of fractures in the next 10 years, based on the presence of risk factors. Given the multifactorial nature of the formation of osteoporotic changes, an integrated approach to the treatment of this disease is necessary. According to the recommendations of the European Society of Endocrinology, bisphosphonates should be considered as first-line therapy. Denosumab, romosozumab, teriparatide can be used as second-line drugs. In addition, given the leading role of hypoestrogenism in the development of postmenopausal osteoporosis, the use of menopausal hormone therapy preparations occupies an important place in the prevention and treatment of osteoporotic changes. An important aspect that determines the effectiveness of the treatment of patients with postmenopausal osteoporosis is the need for interaction between doctors of various specialties, including gynecologists, endocrinologists, rheumatologists, traumatologists, doctors of radiation and laboratory diagnostics.

1. Kanis J.A., Cooper C., Rizzoli R., Reginster J.-Y. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif. Tissue Int. 2019;104(3):235–238. DOI: 10.1007/s00223-018-00512-x

2. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973–997. DOI: 10.1097/GME.0000000000001831

3. Looker A.C., Sarafrazi I.N., Fan B., Shepherd J.A. Trends in osteoporosis and low bone mass in older US adults, 2005–2006 through 2013–2014. Osteoporos Int. 2017;28(6):1979–1988. DOI: 10.1007/s00198-017-3996-1

4. Zakharov I.S., Kolpinskiy G.I., Ushakova G.A., Ushakov A.V., Van W.Ch., Migal O.V., Arkharova O.M. Prevalence of osteopenic syndrome in post menopausal women. Medicine in Kuzbass. 2014;13(3):32–36. (In Russian)

5. McNamara L.M. Osteocytes and estrogen deficiency. Curr. Osteoporos Rep. 2021;19(6):592–603. DOI: 10.1007/s11914-021-00702-x

6. Zakharov I.S., Kolpinskiy G.I., Ushakova G.A., Wavin G.V.The role of oxidative stress in the formation of postmenopausal osteoporosis. Gynecology. 2014;16(1):41–43. (In Russian)

7. Yang C., Ren J., Li B, Jin C., Ma C., Cheng C., Sun Y., Shi X. Identification of gene biomarkers in patients with postmenopausal osteoporosis. Mol. Med. Rep. 2019;19(2):1065–1073. DOI: 10.3892/mmr.2018.9752

8. Fischer V., Haffner-Luntze M. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. Semin. Cell. Dev. Biol. 2022;123:14–21. DOI: 10.1016/j.semcdb.2021.05.014

9. Yan C., Shi Y., Yuan L., Lv D., Sun B., Wang J., Liu X., An F. Mitochondrial quality control and its role in osteoporosis. Front Endocrinol. (Lausanne). 2023;14:1077058. DOI: 10.3389/fendo.2023.1077058

10. Johansson H., Kanis J.A., Odén A. et al. A meta-analysis of the association of fracture risk and body mass index in women. J. Bone Miner. Res. 2014;29(1):223–233. DOI: 10.1002/jbmr.2017

11. Cusano N.E. Skeletal effects of smoking. Curr. Osteoporos Rep. 2015;13(5):302–309. DOI: 10.1007/s11914-015-0278-8

12. Zakharov I.S. Radial diagnostics of osteoporosis — current state of the problem. Polytrauma. 2015;1:69–73. (In Russian)

13. Krueger D., Binkley N., Morgan S. Dual-energy X-ray Absorptiometry Quality Matters. J. Clin. Densitom. 2018;21(2):155–156. DOI: 10.1016/j.jocd.2017.10.002

14. Albano D., Messina C., Vitale J., Sconfienza L.M. Imaging of sarcopenia: old evidence and new insights. Eur. Radiol. 2020;30(4):2199–2208. DOI: 10.1007/s00330-019-06573-2

15. Cozadd A.J., Schroder L.K., Switzer J.A. Fracture Risk Assessment: An Update. J. Bone Joint Surg. Am. 2021;103(13):1238–1246. DOI: 10.2106/JBJS.20.01071

16. Lin W., He C., Xie F., Chen T., Zheng G., Yin H., Chen H., Wang Z. Quantitative CT screening improved lumbar BMD evaluation in older patients compared to dual-energy X-ray absorptiometry. BMC Geriatr. 2023;23(1):231. DOI: 10.1186/s12877-023-03963-6

17. Xu X.M., Li N., Li K., Li X.Y., Zhang P., Xuan Y.J., Cheng X.G. Discordance in diagnosis of osteoporosis by quantitative computed tomography and dual-energy X-ray absorptiometry in Chinese elderly men. J. Orthop. Translat. 2018;18:59–64. DOI: 10.1016/j.jot.2018.11.003

18. Zakharov I.S., Kolpinskiy G.I., Ushakova G.A., Vavin G.V. Biochemical markers in the diagnosis of bone remodeling in osteoporosis. Avicenna Bulletin. 2013;4(57):119–123. (In Russian) DOI: 10.25005/2074-0581-2013-15-4-119-123

19. Parveen B., Parveen A., Vohora D. Biomarkers of Osteoporosis: An Update. Endocr. Metab. Immun. Disord. Drug Targets. 2019;19(7):895–912. DOI: 10.2174/1871530319666190204165207

20. Zhao F., Guo L., Wang X., Zhang Y. Correlation of oxidative stress related biomarkers with postmenopausalosteoporosis: a systematic review and meta-analysis. Arch. Osteoporos. 2021;16(1):4. DOI: 10.1007/s11657-020-00854-w

21. Rosenblat J.D., Gregory J.M., Carvalho A.F., McIntyre R.S. Depression and disturbed bone metabolism: A narrative review of the epidemiological findings and postulated mechanisms. Curr. Mol. Med. 2016;16(2):165–178. DOI: 10.2174/1566524016666160126144303

22. Kuznetsova I.V., Burchakov D.I. Melatonin in treatment of climacteric symptoms. Ginekologiya/ Gynecology. 2015;17(5):44–48. (In Russian)

23. Toffol E., Kalleinen N., Haukka J., Vakkuri O., Partonen T., Polo-Kantola P. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014;21(5):493–500. DOI: 10.1097/GME.0b013e3182a6c8f3

24. Amstrup A.K., Sikjaer T., Heickendorff L. et al. Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial. J. Pineal. Res. 2015;9(2):221–229. DOI: 10.1111/jpi.12252

25. Kotlarczyk M.P., Lassila H.C., O’Neil C.K. et al. Melatonin osteoporosis prevention study (MOPS): a randomized, doubleblind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J. Pineal. Res. 2012;52(4):414–426. DOI: 10.1111/j.1600-079X.2011.00956.x

26. Crandall C.J., Zheng Y., Crawford S.L. et al. Presence of vasomotor symptoms is associated with lower bone mineral density a longitudinal analysis. Menopause. 2009;16(2):239–246. DOI: 10.1097/gme.0b013e3181857964

27. Pal L., Norian J., Zeitlian G. et al. Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil. Steril. 2008;90(5):1626–1634. DOI: 10.1016/j.fertnstert.2007.08.020

28. Kwak K.I., Kang J.H., Kim Y.J., Lee H. A study on the correlation between Menopausal Rating Scale and bone mineral density for menopausal osteoporosis patients. The Acupuncture. 2014;31(3):25–33. DOI: 10.13045/acupunct.2014040

29. Rubin K.H., Abrahamsen B., Friis-Holmberg T. et al. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone. 2013;56(1):16–22. DOI: 10.1016/j.bone.2013.05.002

30. Kanis J.A., Johansson H., Harvey N.C., McCloskey E.V. A brief history of FRAX. Arch. Osteoporos. 2018;13(1):118. DOI: 10.1007/s11657-018-0510-0

31. Vandenput L., Johansson H., McCloskey E.V. Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int. 2022;33(10):2103–2136. DOI: 10.1007/s00198-022-06435-6

32. Eastell R., Rosen C.J., Black D.M. et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2019;104(5):1595–1622. DOI: 10.1210/jc.2019-00221

33. Adams A.L., Adams J.L., Raebel M.A. et al. Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J. Bone Miner. Res. 2018;33(7):1252–1259. DOI: 10.1002/jbmr.3420

34. Kendler D.L., Cosman F., Stad R.K., Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv. Ther. 2022;39(1):58–74. DOI: 10.1007/s12325-021-01936-y

35. Lamy O., Stoll D., Aubry-Rozier B., Rodriguez E.G. Stopping Denosumab. Curr. Osteoporos Rep. 2019;17(1):8–15. DOI: 10.1007/s11914-019-00502-4

36. Kobayakawa T., Miyazaki A., Saito M., Suzuki T., Takahashi J., Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci. Rep. 2021;11(1):11801. DOI: 10.1038/s41598-021-91248-6

37. Barrionuevo P., Kapoor E., Asi N. et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J. Clin. Endocrinol. Metab. 2019;104(5):1623–1630. DOI: 10.1210/jc.2019-00192

38. Melnichenko G.A., Belaya Zh.E., Rozhinskaya L.Ya. et al. Russian clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problemy endokrinologii. 2017;63(6):392–426. (In Russian) DOI: 10.14341/probl2017636392-426

39. Yuan F., Peng W., Yang C., Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int. J. Surg. 2019;66:1–11. DOI: 10.1016/j.ijsu.2019.03.004

40. Muñoz M., Robinson K., Shibli-Rahhal A. Bone health and osteoporosis prevention and treatment. Clin. Obstet. Gynecol. 2020;63(4):770–787. DOI: 10.1097/grf.0000000000000572